Opens in a new tab

Curio Bioscience v 10x Genomics (CoA, 17 December 2024)

Date17 December 2024
CourtCoA
DivisionLuxembourg (LU)
Type of actionApplication Rop 223
Registry referenceApp_66516/2024 · ORD_66752/2024
PartiesCurio Bioscience, Inc v. 10x Genomics, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 17 December 2024 (UPC_CoA_810/2024), the standing judge of the Court of Appeal rejected Curio Bioscience’s application for suspensive effect against the Düsseldorf Local Division’s order of 3 December 2024, which required it to provide security of €200,000 for 10x Genomics’ legal costs within four weeks (EP 2 697 391). The order confirms that suspensive effect remains exceptional, all the more so in an appeal against a procedural order, and that extreme urgency must be established by the applicant, separately from any claim that the impugned order is manifestly wrong.

Question

Do extreme urgency and exceptional circumstances justify suspending an order for security for costs pending an appeal brought under Rule 220.2?

Decision

The standing judge may reject the application without hearing the respondent (paragraph 6). Suspensive effect is granted only in exceptional circumstances, particularly where the impugned order falls under Rule 220.2 (paragraph 8). Curio did not establish extreme urgency: it merely argued that it would have to comply with a manifestly wrong order or risk a default decision (paragraphs 9 and 10). Whether an order is manifestly wrong is a test distinct from urgency. In the light of Rule 158 the order did not appear manifestly wrong, its interplay with Article 69(4) UPCA being a matter for the appeal on the merits (paragraph 11). Curio’s interests did not outweigh those of 10x Genomics and the requirements of due process (paragraph 12).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 41(1), 69(4) and 74(1)
Rules of Procedure
Rules 158, 220.2 and 223
Case law cited
ICPillar v ARM, Court of Appeal, 19 June 2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application Rop 223
Outcome (Dhenne Avocats summary)
La demande d’effet suspensif contre l’ordonnance imposant une garantie pour frais de 200 000 euros est rejetée, faute d’extrême urgence démontrée et de circonstances exceptionnelles.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 697 391
Method and product for localised or spatial detection of nucleic acid in a tissue sample
recorded proprietor: Spatial Transcriptomics AB
Mentioned in the analysis (role not qualified)
Also mentioned in 28 other decision(s): 10x Genomics v Curio Bioscience (CFI, ORD_598272/2023, 30 April 2024) · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_658/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_657/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, 5 August 2025) · 10x Genomics v Curio Bioscience (CFI, 4 August 2025) · 10x Genomics v Curio Bioscience (CFI, 16 June 2025) · 10x Genomics v Curio Bioscience (CFI, 4 June 2025) · 10x Genomics v Curio Bioscience (CFI, 2 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.